Kymera Therapeutics, Inc. (KYMR)

Kymera Therapeutics, Inc.'s Q·Score is 5.8/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. 96% of 23 covering analysts have a positive rating. Key area to monitor: low return on equity (-27%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for KYMR is $118.86, based on ratings from 21 Wall Street analysts. This is 47.3% above the current price of $80.71. Price targets are forward-looking estimates and not guarantees of future performance.

Kymera Therapeutics, Inc. (KYMR) scores in line with sector averages on valuation metrics. The consensus analyst price target of $118.86 is 47% above the current price.

Kymera Therapeutics, Inc. has a net profit margin of 0.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 0.0%, reflecting a more cost-intensive business model.

Kymera Therapeutics, Inc. is reporting strong year-over-year growth of 55.5%.

Kymera Therapeutics, Inc. has a debt-to-equity ratio of 0.05×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 10.81×, indicating comfortable short-term liquidity.